Correlates of weight gain during long-term risperidone treatment in children and adolescents

被引：11

作者：

Calarge C.A. ^{[1
]}

Nicol G. ^{[2
]}

Xie D. ^{[3
]}

Zimmerman B. ^{[4
]}

机构：

[1] Departments of Psychiatry and Pediatrics, The University of Iowa Carver College of Medicine, Iowa City, IA 52242

[2] Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, 660 South Euclid Ave

[3] Departments of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, IA 52242

[4] Biostatistics Consultation Center, The University of Iowa College of Public Health, Iowa City, IA 52242

来源：

Child and Adolescent Psychiatry and Mental Health | / 6卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Adolescent; Antipsychotics; Child; Obesity; Predictors; Risperidone; Weight gain;

D O I：

10.1186/1753-2000-6-21

中图分类号：

学科分类号：

摘要：

Background: Most clinical trials of antipsychotics in children are brief, failing to address their long-term safety, particularly when taken concurrently with other psychotropics. This hypothesis-generating analysis evaluates potential correlates of weight gain in children receiving extended risperidone treatment.Methods: Medically healthy 7-17 year-old patients treated with risperidone for six months or more were enrolled. Anthropometric measurements were conducted. Developmental and medication history was obtained from the medical record. Information related to birth weight, dietary intake, physical activity, and parental weight was collected. Mixed regression analyses explored the contribution of various demographic and clinical factors to age- and sex-adjusted weight and body mass index (BMI) z scores over the treatment period.Results: The sample consisted of 110 patients (89% males) with a mean age of 11.8 years (sd = 2.9) upon enrollment. The majority had an externalizing disorder and received 0.03 mg/kg/day (sd = 0.02) of risperidone, for 2.5 years (sd = 1.7), to primarily target irritability and aggression (81%). Polypharmacy was common with 71% receiving psychostimulants, 50% selective serotonin reuptake inhibitors (SSRIs), and 32% α 2-agonists. Weight and BMI z score were positively correlated with baseline weight at the start of risperidone, treatment duration, and the weight-adjusted dose of risperidone but inversely associated with the weight-adjusted dose of psychostimulants and the concurrent use of SSRIs and α 2-agonists. The effect of risperidone dose appeared to attenuate as treatment extended while that of psychostimulants became more significant. The rate of change in weight (or BMI) z score prior to and within the first 12 weeks of risperidone treatment did not independently predict future changes neither did birth weight, postnatal growth, dietary intake, physical activity, or parental weight.Conclusions: This comprehensive analysis exploring correlates of long-term weight (or BMI) change in risperidone-treated youths revealed that pharmacotherapy exerts significant but complex effects.Trial Registration: Not applicable. © 2012 Calarge et al.; licensee BioMed Central Ltd.

引用

共 68 条

[1]

Comer J.S., Olfson M., Mojtabai R., National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007, Journal of the American Academy of Child and Adolescent Psychiatry, 49, pp. 1001-1010, (2010)

[2]

Olfson M., Crystal S., Huang C., Gerhard T., Trends in antipsychotic drug use by very young, privately insured children, J Am Acad Child Adolesc Psychiatry, 49, pp. 13-23, (2010)

[3]

Medication Guide

[4]

FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal

[5]

Recommendation of Approvable Action for risperidone (Risperdal®) for the Treatment of Schizophrenia and Bipolar I Disorder in Pediatric Patients (response to PWR)

[6]

Findling R.L., Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents, The J Clin Psychiatry, 69, SUPPL. 4, pp. 9-14, (2008)

[7]

Pliszka S.R., Crismon M.L., Hughes C.W., Corners C.K., Emslie G.J., Jensen P.S., McCracken J.T., Swanson J.M., Lopez M., The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder, J A Acad Child Adolesc Psychiatry, 45, pp. 642-657, (2006)

[8]

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months, Am J Psychiatry, 162, pp. 1361-1369, (2005)

[9]

Reyes M., Buitelaar J., Toren P., Augustyns I., Eerdekens M., A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders, Am J Psychiatry, 163, pp. 402-410, (2006)

[10]

Calarge C.A., Acion L., Kuperman S., Tansey M., Schlechte J.A., Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents, J Child Adolesc Psychopharmacol, 19, pp. 101-109, (2009)

← 1 2 3 4 5 6 7 →